EFFECTS OF EMPAGLIFLOZIN IN FEMALE AND MALE PATIENTS WITH HEART FAILURE AND PRESERVED EJECTION FRACTION: RESULTS FROM THE EMPEROR-PRESERVED TRIAL

被引：0
|
作者：
Butler, Javed [1 ]
机构：
[1] Univ Mississippi, Sch Med, Jackson, MS USA
来源：
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY | 2022年 / 79卷 / 09期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：311 / 311
页数：1
相关论文
共 50 条
  • [21] Heart failure with a preserved ejection fraction and the EMPEROR-Preserved Trial: a review of how we got here
    Tiago Tribolet de Abreu
    [J]. Heart Failure Reviews, 2022, 27 : 2077 - 2082
  • [22] Heart failure with a preserved ejection fraction and the EMPEROR-Preserved Trial: a review of how we got here
    de Abreu, Tiago Tribolet
    [J]. HEART FAILURE REVIEWS, 2022, 27 (06) : 2077 - 2082
  • [23] Letter by Gronda et al Regarding Article, "Effect of Empagliflozin on Worsening Heart Failure Events in Patients With Heart Failure and Preserved Ejection Fraction: EMPEROR-Preserved Trial"
    Gronda, Edoardo
    Colivicchi, Furio
    Zuccala, Giuseppe
    [J]. CIRCULATION, 2022, 145 (16) : E839 - E840
  • [24] Empagliflozin improves cardiovascular and renal outcomes in patients with preserved ejection fraction irrespective of age: insights from the EMPEROR-Preserved trial
    Boehm, Michael
    Butler, J.
    Filippatos, G.
    Ferreira, J. P.
    Pocock, S. J.
    Abdin, A.
    Mahfoud, F.
    Brueckmann, M.
    Gollop, N. D.
    Iwata, T.
    Ponikowski, P.
    Wanner, C.
    Zannad, F.
    Packer, M.
    Anker, S. D.
    [J]. EUROPEAN JOURNAL OF HEART FAILURE, 2022, 24 : 131 - 132
  • [25] Plain language summary of the EMPEROR-Preserved study looking at the effect of empagliflozin in patients with heart failure with preserved ejection fraction, with and without diabetes
    Butler, Javed
    Filippatos, Gerasimos
    [J]. FUTURE CARDIOLOGY, 2023, 19 (15) : 723 - 733
  • [26] Impact of empagliflozin on insulin use in patients with heart failure with preserved ejection fraction (HFpEF) and type 2 diabetes: sub-analysis from EMPEROR-Preserved trial
    Butler, J.
    Green, J. B.
    Rosenstock, J.
    [J]. DIABETOLOGIA, 2022, 65 (SUPPL 1) : S285 - S286
  • [27] Drug treatment with empagliflozin was beneficial in people with heart failure with preserved ejection fraction: plain language summary of the EMPEROR-Preserved study
    Zannad, Faiez
    Macari, Steven
    [J]. FUTURE CARDIOLOGY, 2023, 19 (14) : 671 - 677
  • [28] Empagliflozin improves cardiovascular and renal outcomes in patients with preserved ejection fraction irrespective of blood pressure: the EMPEROR-Preserved trial
    Boehm, Michael
    Butler, J.
    Filippatos, G.
    Ferreira, J. P.
    Pocock, S. J.
    Abdin, A.
    Mahfoud, F.
    Brueckmann, M.
    Saloustros, I.
    Schueler, E.
    Ponikowski, P.
    Wanner, C.
    Zannad, F.
    Packer, M.
    Anker, S. D.
    [J]. EUROPEAN JOURNAL OF HEART FAILURE, 2022, 24 : 132 - 132
  • [29] Design and rationale of the EMPagliflozin outcomE tRial in patients with chrOnic heaRt failure (EMPEROR-Preserved)
    Butler, J.
    Packer, M.
    Filippatos, G.
    Zannad, F.
    Salsali, A.
    Kimura, K.
    Schnee, J.
    Zeller, C.
    Pocock, S.
    George, J.
    Brueckmann, M.
    Anker, S. D.
    [J]. EUROPEAN JOURNAL OF HEART FAILURE, 2018, 20 : 232 - 232
  • [30] Empagliflozin and risk of lower respiratory tract infection in heart failure with mildly reduced and preserved ejection fraction: An EMPEROR-Preserved analysis
    Ferreira, Joao Pedro
    Zannad, Faiez
    Packer, Milton
    Filippatos, Gerasimos
    Pocock, Stuart J.
    Vasques-Novoa, Francisco
    Boehm, Michael
    Butler, Javed
    Anker, Stefan
    [J]. EUROPEAN JOURNAL OF HEART FAILURE, 2024, 26 (04) : 952 - 959
12345